Premium
HIF1α‐dependent metabolic reprogramming governs mesenchymal stem/stromal cell immunoregulatory functions
Author(s) -
ContrerasLopez Rafael,
ElizondoVega Roberto,
Paredes Maria Jose,
LuqueCampos Noymar,
Torres Maria Jose,
Tejedor Gautier,
VegaLetter Ana Maria,
FigueroaValdés Aliosha,
Pradenas Carolina,
Oyarce Karina,
Jorgensen Christian,
Khoury Maroun,
GarciaRobles Maria de los Angeles,
Altamirano Claudia,
Djouad Farida,
LuzCrawford Patricia
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201902232r
Subject(s) - mesenchymal stem cell , microbiology and biotechnology , stromal cell , reprogramming , gene silencing , inflammation , mediator , stem cell , chemistry , biology , cell , immunology , cancer research , biochemistry , gene
Hypoxia‐inducible factor 1 α (HIF1α), a regulator of metabolic change, is required for the survival and differentiation potential of mesenchymal stem/stromal cells (MSC). Its role in MSC immunoregulatory activity, however, has not been completely elucidated. In the present study, we evaluate the role of HIF1α on MSC immunosuppressive potential. We show that HIF1α silencing in MSC decreases their inhibitory potential on Th1 and Th17 cell generation and limits their capacity to generate regulatory T cells. This reduced immunosuppressive potential of MSC is associated with a metabolic switch from glycolysis to OXPHOS and a reduced capacity to express or produce some immunosuppressive mediators including Intercellular Adhesion Molecule (ICAM), IL‐6, and nitric oxide (NO). Moreover, using the Delayed‐Type Hypersensitivity murine model (DTH), we confirm, in vivo, the critical role of HIF1α on MSC immunosuppressive effect. Indeed, we show that HIF1α silencing impairs MSC capacity to reduce inflammation and inhibit the generation of pro‐inflammatory T cells. This study reveals the pivotal role of HIF1α on MSC immunosuppressive activity through the regulation of their metabolic status and identifies HIF1α as a novel mediator of MSC immunotherapeutic potential.